Clinical Trial

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult Subjects

Enrolling by Invitation Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of ascending single orally administered doses of F-02-2-Na in adult subjects (to include the Mass Balance) \& multiple orally administered doses of F-02-2-Na in adult subjects with Hyperuricemia.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-01 -> 2026-10-01 2026-06-18
minor Completion pushed: 2026-09-01 -> 2026-12-01 2026-06-18
Trial Details
NCT Number NCT07324434
Lead Sponsor Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.
Collaborators: Xiangbei Welman Pharmaceutical Co., Ltd, Guangzhou Xin-Chuangyi Biopharmaceutical Co., Ltd.
Conditions Hyperuricemia With or Without Gout
Enrollment 69 participants
Start Date 2025-12-15
Primary Completion 2026-10-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-17